You just read:

Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 52 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis

News provided by

Arena Pharmaceuticals, Inc.

Jun 17, 2019, 08:30 ET